Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

Abstract The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBCL with rituximab biosimilars are limited....

Descripció completa

Dades bibliogràfiques

Autors principals:	Mark J. Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, Juan José Bargay Lleonart, Manfred Welslau, SooKyoung Kim, Young N. Lee, Pier L. Zinzani, Kamel Laribi
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2023-02-01
Col·lecció:	eJHaem
Matèries:	biosimilar DLBCL NHL rituximab
Accés en línia:	https://doi.org/10.1002/jha2.593
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!